Available only at Chemist and on line. Support today indicates no worry.
Holder
Printable View
Great news.
BLT
26/03/2020 11:04
MKTUPDTE
PRICE SENSITIVE
REL: 1104 HRS Blis Technologies Limited
MKTUPDTE: BLT: Business update - Essential Business
26 March 2020
Business update - Essential Business
Brian Watson, Chief Executive Officer of Blis Technologies (NZX:BLT), has
confirmed Blis Technologies will remain operational following the Government
overnight raising the national COVID-19 response to Level 4. Blis
Technologies manufacturing and elements of its scientific services are
classified as "essential services". The company has completed the MPI
registration process to maintain that status, and subject to that, they will
continue operating.
As manufacturers of unique probiotics that support immunity, Blis
Technologies is an important supplier to consumers in NZ through pharmacies
and online sales. Essential functions at Blis Technologies will remain
operational during the COVID-19 Level 4 period to ensure BLIS Probiotics can
continue to be supplied to support immunity and throat health of thousands of
New Zealanders during a time of high need and into the winter cold and flu
season.
Blis Technologies is committed to delivering services in accordance with the
Government's guidance to protect the health and wellbeing of all New
Zealanders. Staff that do not have a critical role in manufacture or testing
are working from home. Workplace segregation, social distancing and
sanitisation protocols are fully implemented at both our sites.
We are working closely with our suppliers to ensure continuity of supply.
Ends
For further information, please contact:
Brian Watson
CEO
+64 27 705 9133
Go you Good thing GO
Daily Defence, strawberry, now available on line.
A good article on probiotics below
https://i.stuff.co.nz/life-style/wel...s-good-for-you
Blis is proven to work, they should be supplying information to the journalist.
What about the blind man in Bethsaida
“Then his eyes were opened and he saw everything clearly”
His experience was proof to him.....he could see.
I understand that there have been several clinical trials. You could have a look at these two for a start.
1. Di Pierro F1, Colombo M2, Zanvit A3, Rottoli AS4. Positive clinical
outcomes derived from using Streptococcus salivarius K12 to prevent
streptococcal pharyngotonsillitis in children: a pilot investigation. Drug
Healthc Patient Saf. 2016 Nov 21;8:77-81. eCollection 2016.
2. F. Di Pierro, M. Colombo, M.G. Giuliani, M.L. Danza, I. Basile, T.
Bollani, A.M. Conti, A. Zanvit, A.S. Rottoli. Effect of administration of
Streptococcus salivarius K12 on the occurrence of streptococcal
pharyngo-tonsillitis, scarlet fever and acute otitis media in 3 years old
children. Eur Rev Med Pharmacol Sci Year: 2016 Vol. 20 - N. 21 Pages:
4601-4606.
Below is a link to an Independent Research Report from 2016, this looks like the easiest one place to start looking for information on clinical studies etc.
https://www.nzx.com/announcements/287583
There are several other announcements on studies in Italy and China.
After sending out the link above, I have had a refresher / read and found this interesting information on manufacturing. This is good information considering the recent announcement on the 16th March.
“To date our supply chain, from ingredient supply through to manufacture of finished product has been able to meet the lift in demand and we have significantly increased our production to meet anticipated forward orders. We continue to monitor our supply chain for any future constraints.”
Blis Manufacturing (as at Aug 2016)
Prior to the commissioning of the Birch St facility in Dunedin in September 2013 at a cost of around $0.5m, Blis outsourced lozenge manufacturing to two offshore companies and one based in Nelson. On commissioning of the facility in Dunedin Blis has the capability to produce finished goods including lozenges (bottles and blisters), powders (bottles and sachets) and nutritionals (blended powders in bags and sachets and pre-mix for cans).
The basic ingredient is manufactured by Fonterra (Palmerston North) and shipped to Dunedin with logistics coordinated in Dunedin. The company has plenty of capacity at its Birch street facility to enable future growth.
Current manufacturing in Dunedin is on a single shift only with the ability to triple shift as and when required. Beyond this internal capacity, the company has offshore Lozenge contract manufacturers in Italy and Serbia servicing the EU and several contract manufacturers in the USA.
Blis also contract manufactures for a number of companies with dairy offerings as it holds a Ministry for Primary Industries (MPI) approved registered risk management programme (RMP) status for dairy manufacture. It also manufactures a small number of non-dairy products that require dry blending capability. The company sees the capability as useful as it provides a channel to market for Blis containing nutritional offers in the future.
We understand there has been some risk around raw material supply but the company is in the process of signing a revised supply agreement with Fonterra which will provide capacity to meet near term projections with Fonterra going through an internal process which if approved will serve to increase capacity available to Blis and meet Fonterra’s own needs. Further the company recognizes its single supplier risk and is evaluating alternate sources of supply both in the USA and Europe.